Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
In an effort to increase the reach of its operations in Arizona, WellCare Health Plans, Inc. ( WCG - Snapshot Report ) entered into a definitive agreement with Humana Inc. ( HUM - Analyst Report ) to buy some of the assets of Arcadian Health Plan, Inc.'s Desert Canyon Community Care Medicare Advantage.
If approved by the regulatory bodies, the deal is expected to complete by the end of this year. No other terms of the deal were disclosed.
Per the agreement, starting January 1, 2013, members of Desert Canyon in Mohave and Yavapai will become a part of WellCare in the Arizona region. With this acquisition, the company will cater to a larger section of people as it is committed to providing cost-effective medical assistance to the people of the Arizona region.
With Arizona in its list, WellCare will be extending its services to a dozen states now and serve more than 150,000 Medicare Advantage members and 10,000 Medicare Prescription Drug Plan members.
The announcement comes on the heels of the divestiture initiative undertaken by Humana in order to meet governmental requirements for completing Arcadian Health’s acquisition.
The company also announced that members availing Desert Canyon Medicare Advantage plan will continue to enjoy the same benefits and coverage as earlier in 2012. In case of any changes in the plans and benefits for 2013, the members will be informed.
WellCare has a sound financial position with an increasing cash and cash equivalent balance and comparatively fewer debt obligations. Such strong financials should cushion the company's acquisition procedure. It can either deploy its excess cash or opt for debt financing. Also, It has a decent interest coverage ratio that is way ahead of the sector average.
The recent acquisition is expected to aid WellCare’s net income and help the company in achieving adjusted net income of $5.20 - $5.40 per share in 2012. The acquisition will also increase its customer base that will allow the company to achieve its revenue guidance of $7.0 - $7.1 billion in 2012.
WellCare is scheduled to release its second quarter results before the bell on August 3. The Zacks Consensus Estimate for earnings for the quarter is currently pegged at $1.23 cents per share, representing an estimated year-over-year decrease of 30.5%.
Humana is scheduled to release its second quarter results before the bell on August 6. The Zacks Consensus Estimate for earnings for the quarter is currently pegged at $2.22 cents per share, representing an estimated year-over-year decrease of 11.2%.
WellCare currently retains a Zacks #3 Rank, which translates into a short-term Hold rating. Humana currently retains a Zacks #4 Rank, which translates into a short-term Sell rating.
Read the full reports :
Analyst Report on HUM
Snapshot Report on WCG